WO2023020551A1 - 抗ptk7单域抗体及其应用 - Google Patents
抗ptk7单域抗体及其应用 Download PDFInfo
- Publication number
- WO2023020551A1 WO2023020551A1 PCT/CN2022/113106 CN2022113106W WO2023020551A1 WO 2023020551 A1 WO2023020551 A1 WO 2023020551A1 CN 2022113106 W CN2022113106 W CN 2022113106W WO 2023020551 A1 WO2023020551 A1 WO 2023020551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ptk7
- domain antibody
- single domain
- antibody
- present
- Prior art date
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims abstract description 123
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 16
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 14
- 229940127121 immunoconjugate Drugs 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 12
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 9
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 9
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 9
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 18
- 239000000427 antigen Substances 0.000 abstract description 12
- 230000008685 targeting Effects 0.000 abstract description 10
- 229940125644 antibody drug Drugs 0.000 abstract description 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 101710099452 Inactive tyrosine-protein kinase 7 Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 239000012634 fragment Substances 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- 238000009739 binding Methods 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 102000049511 human PTK7 Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 4
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 4
- 101710130607 Valacyclovir hydrolase Proteins 0.000 description 4
- 102100025139 Valacyclovir hydrolase Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052713 technetium Inorganic materials 0.000 description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 3
- 210000005102 tumor initiating cell Anatomy 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 229950009660 cofetuzumab pelidotin Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000011363 radioimmunotherapy Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- QAAFNSMAIAVCHE-BZLYQNAUSA-N (2s)-2-[(2-amino-2-methylpropanoyl)amino]-n-[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(N)(C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 QAAFNSMAIAVCHE-BZLYQNAUSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- -1 carboxyl amino Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Definitions
- the present invention relates to the field of antibodies, in particular to a specific single-domain antibody against PTK7, and more specifically to its coding sequence and its application in disease diagnosis and treatment.
- PTK7 Protein tyrosine kinase 7
- CCK4 colon cancer kinase 4
- PTK7 is overexpressed in a variety of tumor tissues, including breast cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, and colon cancer, and its overexpression is associated with poor prognosis and increased risk of metastasis.
- PTK7 has also been confirmed to be highly enriched in tumor-initiating cells (TIC) or cancer stem cells in patient-derived tumor tissues. Therefore, targeting PTK7 not only eliminates general cancer cells, but also eliminates TIC responsible for tumor recurrence, becoming a natural candidate for targeted therapy (Damelin, 2017).
- PTK7 has no catalytic activity, it is impractical to develop typical tyrosine kinase inhibitors, and multiple drugs targeting it, including different antibody conjugates and different formats, are in clinical development.
- cofetuzumab pelidotin a new type of antibody-conjugated drug (ADC), using humanized antibody hu6M024 as a targeting carrier and calendulain microtubule inhibitor Aur0101, has been used in metastatic triple-negative breast cancer, platinum-resistant First-in-human clinical trials in ovarian cancer and non-small cell lung cancer.
- F-18-labeled Aptamer aptamer as an immunoimaging tracer targeting PTK7 enabled specific, selective and high-affinity surveillance of PTK7 in xenograft models of several tumor cell lines (HCT116 and UMG) expression, and may further develop PTK7-targeted therapies (Jacobson, 2015).
- Single-domain antibody namely camel heavy chain single-domain antibody VHH (variable domain of heavy chain of heavy-chain antibody)
- VHH variable domain of heavy chain of heavy-chain antibody
- the molecular weight of single-domain antibodies is 1/10 of that of traditional antibodies. It has the characteristics of high stability, good water solubility, simple humanization, high targeting, and strong penetration.
- a radioisotope targeting carrier it can quickly and specifically It can penetrate the tumor tissue and bind the target selectively, and the unbound antibody can be quickly cleared from the blood, reducing the radiation dose of the body.
- D'Huyvetter 2014
- the purpose of the present invention is to provide an anti-PTK7 single domain antibody with good PTK7 antigen binding property.
- the first aspect of the present invention provides a complementarity determining region CDR of the VHH chain of an anti-PTK7 single domain antibody, and the complementarity determining region CDR of the VHH chain comprises:
- the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
- the complementarity determining region CDR of the VHH chain comprises:
- the complementarity determining region CDR of the VHH chain comprises CDR1, CDR2 and CDR3 selected from the following group:
- the second aspect of the present invention provides a VHH chain of an anti-PTK7 single domain antibody, the VHH chain comprising the framework region FR and the complementarity determining region CDR described in the first aspect of the present invention.
- the framework region consists of FR1, FR2, FR3 and FR4 selected from the group consisting of:
- the framework region is composed of:
- the VHH chain of the anti-PTK7 single domain antibody has an amino acid sequence as shown in any one of SEQ ID NO: 1-4.
- the VHH chain of the anti-PTK7 single domain antibody has the amino acid sequence shown in SEQ ID NO:1.
- the third aspect of the present invention provides an anti-PTK7 single-domain antibody, the single-domain antibody is a single-domain antibody against the PTK7 protein, and has a VHH of the amino acid sequence shown in any one of SEQ ID NO: 1-4 chain.
- the single domain antibody has the VHH chain of the amino acid sequence shown in SEQ ID NO:1.
- the fourth aspect of the present invention provides a polynucleotide encoding a protein selected from the group consisting of: the CDR region described in the first aspect of the present invention, the anti-PTK7 monoclonal protein described in the second aspect of the present invention The VHH chain of a domain antibody, or the anti-PTK7 single domain antibody described in the third aspect of the present invention.
- the polynucleotide has a nucleotide sequence as shown in any one of SEQ ID NO.:5-8.
- the polynucleotide includes DNA, cDNA or RNA.
- the fifth aspect of the present invention provides an expression vector containing the polynucleotide described in the fourth aspect of the present invention.
- the expression vector includes: bacterial plasmid, phage, yeast plasmid, plant cell virus, mammalian cell virus such as adenovirus, retrovirus, or other vectors.
- the sixth aspect of the present invention provides a host cell containing the expression vector of the fifth aspect of the present invention, or the polynucleotide of the fourth aspect of the present invention integrated in its genome.
- the host cells include prokaryotic cells or eukaryotic cells.
- the host cell is selected from the group consisting of Escherichia coli and yeast cells.
- the seventh aspect of the present invention provides a method for producing an anti-PTK7 single domain antibody, comprising the steps of:
- the anti-PTK7 single domain antibody has an amino acid sequence as shown in any one of SEQ ID NO: 1-4.
- the eighth aspect of the present invention provides an immunoconjugate comprising:
- VHH chain of the anti-PTK7 single domain antibody according to the second aspect of the present invention, or the anti-PTK7 single domain antibody according to the third aspect of the present invention and (b) a coupling moiety selected from the group consisting of: A marker, drug, toxin, cytokine, radionuclide, or enzyme can be detected.
- the coupling moiety is a drug or a toxin.
- the coupling moiety is a detectable label.
- the conjugate is selected from: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer X-ray tomography) contrast agents, or capable of producing detectable Products of enzymes, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles/nanorods, virus particles, liposomes, nanomagnetic particles, precursors Drug activating enzymes (eg, DT-diaphorase (DTD) or biphenylhydrolase-like protein (BPHL)), chemotherapeutic agents (eg, cisplatin), or nanoparticles in any form, etc.
- DTD DT-diaphorase
- BPHL biphenylhydrolase-like protein
- chemotherapeutic agents eg, cisplatin
- the immunoconjugate contains: the multivalent (such as bivalent) VHH chain of the anti-PTK7 single domain antibody described in the second aspect of the present invention, the anti-PTK7 single domain antibody described in the third aspect of the present invention Anti-PTK7 single domain antibody.
- the multivalent means that the amino acid sequence of the immunoconjugate contains multiple repeats of the VHH chain of the anti-PTK7 single domain antibody described in the second aspect of the present invention, the present invention The anti-PTK7 single domain antibody according to the third aspect.
- the ninth aspect of the present invention provides the VHH chain as described in the second aspect of the present invention, the anti-PTK7 single domain antibody as described in the third aspect of the present invention, or the immunoconjugate as described in the eighth aspect of the present invention
- the purposes of the method are used for preparing (a) reagents for detecting PTK7 molecules; (b) medicines for treating tumors.
- the detection includes flow detection and cell immunofluorescence detection.
- the tumor is a tumor with high expression of PTK7.
- the tumor is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, colon cancer, or a combination thereof.
- the tenth aspect of the present invention provides a pharmaceutical composition comprising: (i) the single domain antibody as described in the third aspect of the present invention or the immunoconjugated antibody as described in the eighth aspect of the present invention substance; and (ii) a pharmaceutically acceptable carrier.
- the pharmaceutical composition is in the form of injection.
- the pharmaceutical composition is used to prepare a drug for treating tumors, and the tumors are selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, colon cancer, or a combination thereof .
- a method for in vitro (diagnostic and non-diagnostic) detection of PTK7 protein in a sample comprising the steps of:
- the twelfth aspect of the present invention provides a method for treating tumors, comprising administering the single domain antibody as described in the third aspect of the present invention, the immunoconjugate as described in the eighth aspect of the present invention to a subject in need, Or the pharmaceutical composition as described in the tenth aspect of the present invention.
- the tumor is a tumor with high expression of PTK7.
- the tumor is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, colon cancer, or a combination thereof.
- the subject includes a human or a non-human mammal.
- the thirteenth aspect of the present invention provides a radioimmunoimaging method, comprising using the single domain antibody as described in the third aspect of the present invention, or the immunoconjugate as described in the eighth aspect of the present invention for imaging.
- Fig. 1 is the detection result of human PTK7-Fc protein antigen. The results showed that the purity of the protein reached more than 90% on SDS-PAGE.
- Figure 2 is the construction and quality inspection results of two anti-PTK7 single domain antibody phage display libraries.
- Figure A is the PCR identification diagram of the first and second PCR amplification products of the two libraries. The results show that a VHH gene fragment with a size of about 400bp is finally obtained;
- Figure B is the storage capacity detection diagram of the two libraries.
- Fig. 3 is the result of flow cytometry detection of the binding activity of anti-PTK7 single domain antibody to PTK7-positive HCT116 cells. The results showed that all four single-domain antibodies could effectively bind to PTK7 protein on the surface of HCT116 cells.
- the present invention utilizes human-derived PTK7 extracellular segment antigen protein to immunize camels to obtain a high-quality immune single-domain antibody gene library. Then the PTK7 protein molecule is coupled to the microtiter plate to display the correct spatial structure of the PTK7 protein, and the antigen in this form is screened by the phage display technology for the immune single-domain antibody gene library (camel heavy chain antibody phage display gene library) to obtain PTK7-specific single domain antibody gene. The gene was then transferred to E. coli to obtain a single-domain antibody strain that can be highly expressed in E. coli and has high specificity.
- human-derived PTK7 extracellular segment antigen protein to immunize camels to obtain a high-quality immune single-domain antibody gene library. Then the PTK7 protein molecule is coupled to the microtiter plate to display the correct spatial structure of the PTK7 protein, and the antigen in this form is screened by the phage display technology for the immune single-domain antibody gene library (camel heavy chain
- single domain antibody of the present invention As used herein, the terms “single domain antibody of the present invention”, “anti-PTK7 single domain antibody of the present invention”, and “PTK7 single domain antibody of the present invention” are used interchangeably, and all refer to specific recognition and binding to PTK7 (including human, Single domain antibodies to mouse and monkey PTK7).
- the present invention includes the single-domain antibody whose amino acid sequence is as described in any one of SEQ ID NO: 1-4, particularly preferably the single-domain antibody whose VHH chain amino acid sequence is as shown in SEQ ID NO: 1.
- single domain antibody As used herein, the terms “single domain antibody”, “VHH”, and “nanobody” have the same meaning and are used interchangeably, and refer to the variable region of the heavy chain of a cloned antibody, constructed from only one heavy chain variable region.
- a single-domain antibody composed of domains, which is the smallest fully functional antigen-binding fragment.
- CH1 light chain and heavy chain constant region 1
- the variable region of the heavy chain of the antibody is cloned to construct a single domain antibody (VHH) consisting of only one heavy chain variable region.
- antibody or "immunoglobulin” is a heterotetrameric protein of about 150,000 Daltons with identical structural features, consisting of two identical light (L) chains and two identical heavy chains (H) Composition. Each light chain is linked to a heavy chain by one covalent disulfide bond, and the number of disulfide bonds varies between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable region (VH) at one end followed by constant regions.
- VH variable region
- Each light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite the first constant region of the heavy chain, and the variable region of the light chain is opposite the variable region of the heavy chain .
- VL variable region
- Specific amino acid residues form the interface between the variable domains of the light and heavy chains.
- variable means that certain portions of the variable regions among antibodies differ in sequence, which contribute to the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout antibody variable domains. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the light and heavy chain variable regions. The more conserved portions of the variable domains are called the framework regions (FR).
- CDRs complementarity determining regions
- FR framework regions
- the variable domains of native heavy and light chains each contain four FR regions that are roughly in a ⁇ -sheet configuration connected by three CDRs that form connecting loops, in some cases forming partial ⁇ -sheet structures.
- the CDRs in each chain are brought into close proximity by the FR regions and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)).
- the constant regions are not directly involved in the binding of the antibody to the antigen, but they exhibit different effector functions, for example involved in the antibody-dependent cytotoxicity of the antibody.
- variable region and “complementarity determining region (CDR)” are used interchangeably.
- the heavy chain variable region of the antibody includes three complementarity determining regions CDR1, CDR2, and CDR3.
- the heavy chain of the antibody includes the above-mentioned heavy chain variable region and heavy chain constant region.
- antibody of the present invention protein of the present invention
- polypeptide of the present invention are used interchangeably, and all refer to polypeptides that specifically bind to the PTK7 protein, such as proteins or polypeptides with heavy chain variable regions . They may or may not contain starting methionine.
- the invention also provides other proteins or fusion expression products having the antibodies of the invention.
- the present invention includes any protein or protein conjugates and fusion expression products (i.e., immunoconjugates and fusion expression products) having a heavy chain containing a variable region, as long as the variable region is compatible with the heavy chain of the antibody of the present invention
- the variable regions are identical or at least 90% homologous, preferably at least 95% homologous.
- variable regions which are separated into four framework regions (FRs), and the amino acid sequences of the four FRs It is relatively conservative and does not directly participate in the binding reaction.
- CDRs form a ring structure, and the ⁇ sheets formed by the FRs in between are close to each other in the spatial structure.
- the CDRs on the heavy chain and the corresponding CDRs on the light chain constitute the antigen-binding site of the antibody. Which amino acids constitute FR or CDR regions can be determined by comparing the amino acid sequences of antibodies of the same type.
- variable regions of the heavy chains of the antibodies of the invention are of particular interest because at least some of them are involved in binding antigen. Therefore, the present invention includes those molecules having antibody heavy chain variable regions with CDRs, as long as the CDRs have more than 90% (preferably more than 95%, most preferably more than 98%) homology to the CDRs identified herein sex.
- the present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Accordingly, the invention also includes fragments, derivatives and analogs of said antibodies.
- fragment refers to a polypeptide that substantially retains the same biological function or activity of the antibody of the present invention.
- the polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide in combination with another compound (such as a compound that extends the half-life of the polypeptide, e.g.
- polyethylene glycol polyethylene glycol
- an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
- an additional amino acid sequence fused to the polypeptide sequence such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or with fusion protein formed by 6His tag.
- the antibody of the present invention refers to a polypeptide that has PTK7 protein binding activity and includes the above CDR region.
- the term also includes variant forms of polypeptides comprising the above CDR regions that have the same function as the antibodies of the present invention. These variations include (but are not limited to): deletion, insertion and/or substitution of one or more amino acids, and addition of one or several amino acids at the C-terminal and/or N-terminal. For example, in the art, substitutions with amino acids with similar or similar properties generally do not change the function of the protein. As another example, adding one or several amino acids at the C-terminus and/or N-terminus usually does not change the function of the protein.
- the term also includes active fragments and active derivatives of the antibodies of the invention.
- Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA hybrids that can hybridize with the DNA encoding the antibody of the present invention under high or low stringency conditions
- the encoded protein, and the polypeptide or protein obtained by using the antiserum against the antibody of the present invention.
- the invention also provides other polypeptides, such as fusion proteins comprising single domain antibodies or fragments thereof.
- the invention also includes fragments of the single domain antibodies of the invention.
- the fragment has at least about 50 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids of an antibody of the invention.
- “conservative variants of the antibody of the present invention” refer to at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acid sequences compared with the amino acid sequence of the antibody of the present invention.
- An amino acid is replaced by an amino acid with similar or similar properties to form a polypeptide.
- These conservative variant polypeptides are preferably produced by amino acid substitutions according to Table A.
- the present invention also provides polynucleotide molecules encoding the above-mentioned antibodies or fragments or fusion proteins thereof.
- a polynucleotide of the invention may be in the form of DNA or RNA.
- Forms of DNA include cDNA, genomic DNA or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- DNA can be either the coding strand or the non-coding strand.
- a polynucleotide encoding a mature polypeptide of the present invention includes: a coding sequence that encodes only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optional additional coding sequences) and non-coding sequences .
- polynucleotide encoding a polypeptide may include a polynucleotide encoding the polypeptide, or may also include additional coding and/or non-coding sequences.
- the present invention also relates to polynucleotides that hybridize to the above-mentioned sequences and have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences.
- the invention particularly relates to polynucleotides which are hybridizable under stringent conditions to the polynucleotides of the invention.
- stringent conditions refers to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2 ⁇ SSC, 0.1% SDS, 60°C; or (2) hybridization with There are denaturing agents, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, etc.; or (3) only if the identity between the two sequences is at least 90%, more Preferably, hybridization occurs above 95%.
- the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
- the full-length nucleotide sequence of the antibody of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis.
- a feasible method is to use artificial synthesis to synthesize related sequences, especially when the fragment length is short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.
- the coding sequence of the heavy chain and an expression tag (such as 6His) can also be fused together to form a fusion protein.
- biomolecules nucleic acid, protein, etc.
- the biomolecules involved in the present invention include biomolecules in an isolated form.
- the DNA sequence encoding the protein of the present invention (or its fragments, or its derivatives) can be obtained completely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or eg vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequences of the invention by chemical synthesis.
- the present invention also relates to vectors comprising the above-mentioned appropriate DNA sequences and appropriate promoter or control sequences. These vectors can be used to transform appropriate host cells so that they express the protein.
- the host cell may be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
- a prokaryotic cell such as a bacterial cell
- a lower eukaryotic cell such as a yeast cell
- a higher eukaryotic cell such as a mammalian cell.
- Representative examples are: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS7, 293 cells, etc.
- Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art.
- competent cells capable of taking up DNA can be harvested after the exponential growth phase and treated with the CaCl2 method using procedures well known in the art. Another method is to use MgCl2 . Transformation can also be performed by electroporation, if desired.
- DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
- the obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention.
- the medium used in the culture can be selected from various conventional media according to the host cells used.
- the culture is carried out under conditions suitable for the growth of the host cells. After the host cells have grown to an appropriate cell density, the selected promoter is induced by an appropriate method (such as temperature shift or chemical induction), and the cells are cultured for an additional period of time.
- the recombinant polypeptide in the above method can be expressed inside the cell, or on the cell membrane, or secreted outside the cell.
- the recombinant protein can be isolated and purified by various separation methods by taking advantage of its physical, chemical and other properties, if desired. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitating agents (salting out method), centrifugation, osmotic disruption, supertreatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- the antibodies of the invention can be used alone, or combined or conjugated with a detectable label (for diagnostic purposes), a therapeutic agent, a PK (protein kinase) modifying moiety, or a combination of any of these.
- Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or substances capable of producing a detectable product. enzyme.
- Therapeutic agents that can be combined or coupled with the antibody of the present invention include but are not limited to: 1. Radionuclide; 2. Biological toxicity; 3. Cytokines such as IL-2, etc.; 4. Gold nanoparticles/nanorods; 5. Viruses 6. Liposomes; 7. Nanomagnetic particles; 8. Drug-activating enzymes (eg, DT-diaphorase (DTD) or biphenylhydrolase-like protein (BPHL)); 9. Therapeutic agents (eg, , cisplatin) or any form of nanoparticles, etc.
- DTD DT-diaphorase
- BPHL biphenylhydrolase-like protein
- the present invention also provides a composition.
- the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein, and a pharmaceutically acceptable carrier.
- these materials can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is usually about 5-8, preferably about 6-8, although the pH value can be changed according to the Depending on the nature of the substance formulated and the condition to be treated.
- the formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or topical administration.
- the pharmaceutical composition of the invention can be directly used for binding PTK7 protein molecules, and thus can be used for treating tumors.
- other therapeutic agents may also be used concomitantly.
- the pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned single domain antibody (or its conjugate) of the present invention and pharmaceutical acceptable carrier or excipient.
- Such carriers include, but are not limited to: saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
- the pharmaceutical formulation should match the mode of administration.
- the pharmaceutical composition of the present invention can be prepared in the form of injection, for example, by conventional methods using physiological saline or aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably produced under sterile conditions.
- the active ingredient is administered in a therapeutically effective amount, for example about 10 micrograms/kg body weight to about 50 mg/kg body weight per day.
- the polypeptides of the invention can also be used with other therapeutic agents.
- a safe and effective amount of the immunoconjugate is administered to the mammal, wherein the safe and effective amount is usually at least about 10 micrograms/kg body weight, and in most cases no more than about 50 mg/kg body weight, Preferably the dose is about 10 micrograms/kg body weight to about 10 mg/kg body weight.
- the route of administration and the health status of the patient should also be considered for the specific dosage, which are within the skill of skilled physicians.
- the single domain antibody bears a detectable label. More preferably, the label is selected from the group consisting of isotopes, colloidal gold labels, colored labels or fluorescent labels.
- Colloidal gold labeling can be performed using methods known to those skilled in the art.
- the anti-PTK7 single-domain antibody is labeled with colloidal gold to obtain a colloidal gold-labeled single-domain antibody.
- the anti-PTK7 single-domain antibody is labeled with a radioactive isotope to obtain an isotope-labeled single-domain antibody.
- the anti-PTK7 single domain antibody of the invention has good specificity and high titer, and can be used for clinical diagnosis against PTK7.
- the present invention also relates to methods for detecting PTK7 protein.
- the steps of the method are roughly as follows: obtaining a cell and/or tissue sample; dissolving the sample in a medium; detecting the level of PTK7 protein in the dissolved sample.
- the sample used is not particularly limited, and a representative example is a cell-containing sample present in a cell preservation solution.
- the present invention also provides a kit containing the antibody (or a fragment thereof) or a detection plate of the present invention.
- the kit further includes a container, an instruction manual, a buffer and the like.
- the present invention also provides a detection kit for detecting the level of PTK7, which includes an antibody that recognizes PTK7 protein, a lysis medium for dissolving samples, general reagents and buffers required for detection, such as various buffers, detection labeling, detection substrates, etc.
- the test kit may be an in vitro diagnostic device.
- the single domain antibody of the present invention has a wide range of biological and clinical application values, and its application involves the diagnosis and treatment of diseases related to PTK7, basic medical research, biological research and other fields.
- a preferred application is for clinical diagnosis and targeted therapy against PTK7.
- the present invention provides the application of anti-PTK7 single domain antibody in the diagnosis and treatment of tumors, which are tumors with abnormally high expression of PTK7 (including mRNA and/or protein levels), specifically, the tumors include but not limited to: breast cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, colon cancer, etc.
- the present invention has developed a single-domain antibody against the PTK7 target for the first time
- the single domain antibody of the present invention has good specificity and can bind to human, mouse and rhesus monkey PTK7;
- the single-domain antibody of the present invention can effectively accumulate in PTK7 high-expression tumor models, and can be applied to PTK7-targeted cancer diagnosis and curative effect evaluation, and can be used to develop a new generation of PTK7-targeted therapy;
- Embodiment 1 Human PTK7-Fc protein antigen expression
- Transient expression of human PTK7 extracellular domain protein in mammalian cells HEK293F Cloning human PTK7 extracellular domain gene into pFUSE-IgG recombinant plasmid, mixed with transfection reagent PEI 1:3, and then transfected into HEK293F cells; 37°C, 6 Culture in a %CO2 shaker incubator for 6 days; then collect the cell supernatant and combine with Protein A beads at room temperature for 1 hour; wash the beads with phosphate buffer solution pH 7.0, and elute the protein with 0.1M pH 3.0 glycine solution ; Then the eluted protein was ultrafiltered into PBS solution, and after measuring the yield, samples were taken for SDS-PAGE detection.
- the purified PTK7-Fc protein was used to immunize two Xinjiang Bactrian camels. After seven immunizations, the total RNA was isolated from the peripheral blood of the camels, and the VHH gene was amplified by reverse transcription and PCR (Fig. 2A). Cloned into the phage vector pMECS, transformed into TG1 host cells to construct a phage display library. The two constructed libraries were serially diluted and plated to determine the library capacity. At the same time, 24 clones were randomly selected from each constructed library for colony PCR detection.
- each plasmid was electrotransformed into Escherichia coli WK6, spread on the culture plate of LA+glucose, and cultivated overnight at 37°C; a single colony was selected and inoculated on Cultivate in 5 mL of LB culture medium containing ampicillin overnight at 37°C on a shaker; inoculate 1 mL of the overnight strain into 330 mL of TB culture liquid, and culture on a shaker at 37°C. Cultivate overnight on a shaking table; collect bacteria by centrifugation, and obtain crude antibody extract by osmosis method; prepare purified single domain antibody by nickel column ion affinity chromatography. After testing, the purity of the expressed and purified single domain antibody was greater than 90%, which was used for candidate functional activity research, and finally obtained the following 4 leading single domain antibody strains.
- Antibody number Amino acid sequence number Nucleotide sequence number MY2132-4-22 SEQ ID NO: 1 SEQ ID NO: 5 MY2132-4-55 SEQ ID NO: 2 SEQ ID NO: 6 MY2132-4-79 SEQ ID NO: 3 SEQ ID NO: 7 MY2132-5-51 SEQ ID NO: 4 SEQ ID NO: 8
- sequences of the four single domain antibodies are as follows, and the three CDR regions are underlined respectively.
- Example 4 Enzyme-linked immunoassay (ELISA) detection of anti-PTK7 single domain antibody and different species of PTK7
- PTK7-Fc of human or mouse species or PTK7-His antigen protein of rhesus monkey species to prepare the microtiter plate, overnight at 4°C; wash 4 times with PBS-T the next day, add 1% BSA, and keep at room temperature Block for 2 hours; wash 4 times with PBS-T, add anti-PTK7 single domain antibody diluted according to gradient, place at 37°C for 1 hour; wash 4 times with PBS-T, add mouse anti-His-HRP antibody or mouse anti-HA-HRP Antibody, placed at 37°C for 1 hour; washed 4 times with PBS-T, added TMB soluble substrate, and left at room temperature for 10 minutes; read the absorbance value at 450nm wavelength, and calculated the Kd value of each single domain antibody according to the absorbance value.
- the test results are shown in Table 2.
- the anti-PTK7 single domain antibody of the present invention can bind to human, mouse or rhesus monkey PTK7.
- the stationary phase human PTK7-Fc antigen protein was immobilized on the surface of the CM-5 sensor chip by carboxyl amino reaction; the anti-PTK7 single domain antibody was diluted to different concentrations with HBS buffer, and the anti-PTK7 single domain antibody was added at a flow rate of 30ul/min. Combining for 90s and dissociation for 600s, observe the binding process of anti-PTK7 single domain antibody and antigen; wash with 10mM Glycine for chip regeneration, and proceed to the next anti-PTK7 single domain antibody determination.
- Example 6 ELISA detection of anti-PTK7 single domain antibody and human PTK7 epitope identification group
- the test results are shown in Table 5.
- the anti-PTK7 single domain antibody of the present invention can be divided into two groups according to the binding epitope, wherein MY2132-4-22 is group 1, MY2132-4-55, MY2132-4-79 and MY2132-5 -51 for group 2.
- Antibody binding function verification was carried out using the tumor cell HCT116 with high expression of PTK7: the cultured BxPc3 cells were digested with trypsin and neutralized with complete medium, and the cells were washed once with PBS, and then the cells were collected; the cells were evenly distributed into 96-well plates, Add human Fc blocking antibody, incubate at 4°C for 15 minutes; wash cells once with PBS after centrifugation, add anti-PTK7 single domain antibody or non-targeting single domain antibody (negative control), incubate at 4°C for 30 minutes; wash with PBS after centrifugation Cells once, then add anti-HA-Alexa Fluor488 or mouse anti-PTK7-FITC antibody (positive control), incubate at 4°C for 20 minutes; wash the cells once with PBS, centrifuge at 4°C for 5 minutes, discard the supernatant, add 200ul PBS to re-incubate Suspend the cells, and detect the Alexa Fluor488 signal of each sample by flow
- the anti-PTK7 single domain antibody of the present invention can effectively bind to the PTK7 protein on the surface of tumor cells.
- Example 8 SPECT/CT Imaging of Anti-PTK7 Single Domain Antibody in Mouse Tumor Xenograft Model
- the anti-PTK7 single domain antibody of the present invention can effectively accumulate in PTK7 high-expression tumor models, and is applied to PTK7-targeted cancer diagnosis and curative effect evaluation, and at the same time, develops a new generation of PTK7-targeted therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
组 | CDR1序列编号 | CDR2序列编号 | CDR3序列编号 |
1 | 9 | 12 | 15 |
2 | 10 | 13 | 16 |
3 | 10 | 13 | 17 |
4 | 11 | 14 | 18。. |
组 | FR1序列编号 | FR2序列编号 | FR3序列编号 | FR4序列编号 |
1 | 19 | 22 | 25 | 29 |
2 | 20 | 23 | 26 | 30 |
3 | 20 | 23 | 27 | 29 |
4 | 21 | 24 | 28 | 31。 |
最初的残基 | 代表性的取代 | 优选的取代 |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
抗体编号 | 氨基酸序列编号 | 核苷酸序列编号 |
MY2132-4-22 | SEQ ID NO:1 | SEQ ID NO:5 |
MY2132-4-55 | SEQ ID NO:2 | SEQ ID NO:6 |
MY2132-4-79 | SEQ ID NO:3 | SEQ ID NO:7 |
MY2132-5-51 | SEQ ID NO:4 | SEQ ID NO:8 |
抗体编号 | K on(1/Ms) | K off(1/s) | Kd(nM) |
MY2132-4-22 | 1.51E+07 | 3.22E-02 | 2.13 |
MY2132-4-55 | 1.76E+06 | 3.14E-04 | 0.18 |
MY2132-4-79 | 1.64E+06 | 3.58E-04 | 0.22 |
MY2132-5-51 | 4.82E+05 | 1.66E-03 | 3.45 |
抗体编号 | MY2132-4-22 | MY2132-4-55 | MY2132-4-79 | MY2132-5-51 | 结论 |
MY2132-4-22 | 竞争 | 非竞争 | 非竞争 | 非竞争 | 1 |
MY2132-4-55 | 非竞争 | 竞争 | 竞争 | 竞争 | 2 |
MY2132-4-79 | 非竞争 | 竞争 | 竞争 | 竞争 | 2 |
MY2132-5-51 | 非竞争 | 竞争 | 竞争 | 竞争 | 2 |
Claims (15)
- 一种抗PTK7单域抗体VHH链的互补决定区CDR,其特征在于,所述VHH链的互补决定区CDR包含:SEQ ID NO:9-11任一项所示的CDR1;SEQ ID NO:12-14任一项所示的CDR2;和SEQ ID NO:15-18任一项所示的CDR3。
- 如权利要求1所述的互补决定区CDR,其特征在于,包含选自下组的CDR1、CDR2和CDR3:
组 CDR1序列编号 CDR2序列编号 CDR3序列编号 1 9 12 15 2 10 13 16 3 10 13 17 4 11 14 18。. - 一种抗PTK7单域抗体的VHH链,所述VHH链包括框架区FR和权利要求1所述的互补决定区CDR。
- 一种抗PTK7单域抗体,其特征在于,所述单域抗体是针对PTK7蛋白的单域抗体,并且具有如SEQ ID NO:1-4任一所示的氨基酸序列的VHH链。
- 一种多核苷酸,其特征在于,所述多核苷酸编码选自下组的蛋白质:权利要求1所述的CDR区、权利要求2所述的抗PTK7单域抗体的VHH链、或权利要求3所述的抗PTK7单域抗体。
- 如权利要求5所述的多核苷酸,其特征在于,所述多核苷酸具有如SEQ ID NO.:5-8任一所示的核苷酸序列。
- 一种表达载体,其特征在于,所述表达载体含有权利要求5所述的多核苷酸。
- 一种宿主细胞,其特征在于,所述宿主细胞含有权利要求7所述的表达载体,或其基因组中整合有权利要求5所述的多核苷酸。
- 一种产生抗PTK7单域抗体的方法,其特征在于,包括步骤:(a)在适合产生单域抗体的条件下,培养权利要求8所述的宿主细胞,从而获得含所述抗PTK7单域抗体的培养物;以及(b)从所述培养物中分离或回收所述的抗PTK7单域抗体。
- 一种免疫偶联物,其特征在于,该免疫偶联物含有:(a)如权利要求3所述的抗PTK7单域抗体的VHH链、或如权利要求3所述的抗PTK7单域抗体;和(b)选自下组的偶联部分:可检测标记物、药物、毒素、细胞因子、放射性核素、或酶。
- 如权利要求3所述的VHH链,如权利要求4所述的抗PTK7单域抗体,或如权利要求10所述的免疫偶联物的用途,其特征在于,用于制备(a)用于检测PTK7分子的试剂;(b)用于***的药物。
- 如权利要求11所述的用途,其特征在于,所述肿瘤为PTK7高表达的肿瘤。
- 一种药物组合物,其特征在于,所述药物组合物包含:(i)如权利要求4所述的单域抗体或如权利要求10所述的免疫偶联物;和(ii)药学上可接受的载体。
- 一种体外(诊断和非诊断性)检测样品中PTK7蛋白的方法,包括步骤:(1)将样品与权利要求4所述的单域抗体接触;(2)检测是否形成抗原-抗体复合物,其中形成复合物就表示样品中存在PTK7蛋白。
- 一种***的方法,包括向需要的对象施用如权利要求4所述的单域抗体,如权利要求10所述的免疫偶联物,或如权利要求13所述的药物组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022329227A AU2022329227A1 (en) | 2021-08-18 | 2022-08-17 | Anti-ptk7 single-domain antibody and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110950740.1 | 2021-08-18 | ||
CN202110950740.1A CN115894696A (zh) | 2021-08-18 | 2021-08-18 | 抗ptk7单域抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023020551A1 true WO2023020551A1 (zh) | 2023-02-23 |
Family
ID=85240098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/113106 WO2023020551A1 (zh) | 2021-08-18 | 2022-08-17 | 抗ptk7单域抗体及其应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN115894696A (zh) |
AU (1) | AU2022329227A1 (zh) |
WO (1) | WO2023020551A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101360761A (zh) * | 2005-12-08 | 2009-02-04 | 米德列斯公司 | 抗蛋白质酪氨酸激酶7(ptk7)的人单克隆抗体及其用途 |
CN101939028A (zh) * | 2007-11-30 | 2011-01-05 | 百时美施贵宝公司 | 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 |
CN103547597A (zh) * | 2011-02-18 | 2014-01-29 | 施特姆森特Rx股份有限公司 | 新型调节剂及使用方法 |
CN106659801A (zh) * | 2014-04-30 | 2017-05-10 | 辉瑞大药厂 | 抗‑ptk7抗体‑药物缀合物 |
CN109485726A (zh) * | 2017-09-13 | 2019-03-19 | 和迈生物科技有限公司 | 放射性标记抗纳米抗体在癌症的预后、诊断中的应用 |
CN112955472A (zh) * | 2018-11-07 | 2021-06-11 | 克里斯珀医疗股份公司 | 抗ptk7免疫细胞癌症疗法 |
-
2021
- 2021-08-18 CN CN202110950740.1A patent/CN115894696A/zh active Pending
-
2022
- 2022-08-17 WO PCT/CN2022/113106 patent/WO2023020551A1/zh active Application Filing
- 2022-08-17 AU AU2022329227A patent/AU2022329227A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101360761A (zh) * | 2005-12-08 | 2009-02-04 | 米德列斯公司 | 抗蛋白质酪氨酸激酶7(ptk7)的人单克隆抗体及其用途 |
CN101939028A (zh) * | 2007-11-30 | 2011-01-05 | 百时美施贵宝公司 | 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 |
CN103547597A (zh) * | 2011-02-18 | 2014-01-29 | 施特姆森特Rx股份有限公司 | 新型调节剂及使用方法 |
CN106659801A (zh) * | 2014-04-30 | 2017-05-10 | 辉瑞大药厂 | 抗‑ptk7抗体‑药物缀合物 |
CN109485726A (zh) * | 2017-09-13 | 2019-03-19 | 和迈生物科技有限公司 | 放射性标记抗纳米抗体在癌症的预后、诊断中的应用 |
CN112955472A (zh) * | 2018-11-07 | 2021-06-11 | 克里斯珀医疗股份公司 | 抗ptk7免疫细胞癌症疗法 |
Non-Patent Citations (6)
Title |
---|
DAMELIN, M. ET AL.: "A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions", SCI.TRANSL.MED., vol. 9, 11 January 2017 (2017-01-11), XP055714349, DOI: 10.1126/scitranslmed.aag2611 * |
FERRARI NICOLA, WARD GEORGE, GEWINNER CHRISTINA, DAVIS MATTHEW P., JUELIGER SIMONE, SAINI HARPREET, MUNCK JOANNE, SMYTH TOMOKO, FE: "Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma", BLOOD ADVANCES, vol. 5, no. 20, 26 October 2021 (2021-10-26), pages 4003 - 4016, XP093036702, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2020003955 * |
KABAT ET AL.: "NIH Publ. No. 91-3242", vol. I, 1991, pages: 647 - 669 |
SAMBROOK J ET AL.: "Molecular Cloning: A Laboratory Manual", 2002, SCIENCE PRESS |
YANG EMILY Y., SHAH KHALID: "Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics", FRONTIERS IN ONCOLOGY, vol. 10, XP055793895, DOI: 10.3389/fonc.2020.01182 * |
YAOZHONG HU, CHANGXIAO LIU, SERGE MUYLDERMANS: "Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy", FRONTIERS IN IMMUNOLOGY, vol. 8, XP055488468, DOI: 10.3389/fimmu.2017.01442 * |
Also Published As
Publication number | Publication date |
---|---|
CN115894696A (zh) | 2023-04-04 |
AU2022329227A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11466085B2 (en) | Anti-PD-L1 nanobody, coding sequence and use thereof | |
ES2899036T3 (es) | Nanocuerpo anti-PD-L1 y su uso | |
CN109096396B (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
US20230263916A1 (en) | Anti-her2 nanobody and coding sequence and use thereof | |
CN111518212B (zh) | 抗Trop2纳米抗体及其应用 | |
US20230399395A1 (en) | Anti-il5 nanoantibody and use thereof | |
JP2020533370A (ja) | 癌の予後と診断における放射性標識抗pd−l1ナノボディの応用 | |
WO2023142309A1 (zh) | 抗tslp纳米抗体及其应用 | |
US20220411519A1 (en) | Anti-il-4r single-domain antibody and use thereof | |
WO2023274365A1 (zh) | 抗trop2单域抗体及其应用 | |
WO2023125842A1 (zh) | 一种新型upar单域抗体的开发 | |
WO2023020551A1 (zh) | 抗ptk7单域抗体及其应用 | |
CN118139893A (zh) | 抗ptk7单域抗体及其应用 | |
WO2023116781A1 (zh) | 一种新型pd1单域抗体的开发 | |
CN116333121A (zh) | 一种新型靶向cd33单域抗体的开发 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22857862 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022329227 Country of ref document: AU Ref document number: AU2022329227 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022329227 Country of ref document: AU Date of ref document: 20220817 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022857862 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022857862 Country of ref document: EP Effective date: 20240318 |